EMVision Medical Devices (ASX:EMV) said five of the six validation trial sites for its emu bedside brain scanner are actively enrolling and scanning patients, according to a Wednesday Australian bourse filing.
Recruitment is currently ongoing at its third US-based site in New York. The final sixth site for the validation trial recently cleared its local institutional review board.
The validation trial has an estimated enrollment period of six to 12 months, and up to 300 suspected stroke patients will be enrolled across four sites in the US and two sites in Australia.
The firm also secured ethics approval to begin scanning patients with suspected stroke or traumatic brain injury at Princess Alexandra Hospital in Brisbane, Queensland, and John Hunter Hospital in Newcastle, New South Wales. It will use the results for continued device innovation, algorithm enhancement, and data to support indication expansion.
Its shares rose 3% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.